Adrian Newman-Tancredi
is also co-founder and
Chief Scientific Officer
Neurolixis Inc.



Adrian Newman-Tancredi is PI of a supplementary research grant that has been awarded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Neurolixis Inc. Adrian is...Read More
Alzheimer disease is associated with profound changes in neurotransmitter regulation in the brain. The hippocampus is one brain region that regulates memory and serotonin 5-HT1A...Read More
Adrian Newman-Tancredi will be chairing a session at an online neuroscience conference taking place from 17th to 19th June 2014. The webinar, organized by the online life-science...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.




    NeuroAct Communication

    offers professional and independent advice

    at each stage of early CNS drug discovery. 


    Consulting Services




    Read the latest news from NeuroAct Communication



    April 2014

    November 2013




    NeuroAct Communication  

    was founded by Adrian Newman-Tancredi PhD DSc

    an experienced industrial neuropharmacologist.


    Executive Profile




    Expertise in CNS Drug Discovery

    Preclinical pharmacology of antipsychotics,
    antidepressants, anti-Parkinsonian drugs and analgesics.   


    Read more